COMPANY

  • Home
  • Company | History
We are Making constant efforts to develop the next-generation biopharmaceutical new drugs based on our management value of 'fusion' and 'challenge'.
  • Present ~ 2010
  • 2002 ~2009
  • 2020

    - Cellgram-AKI, an allogeneic mesenchymal stem cell therapy for the treatment of COVID-19, approved for use in treatment (KFDA)

    - Patent registration : Method for Producing Monocyte Derived From Bone Marrow

  • 2019

    - Patent registration : Composition for Inducing Maturation of Next-Generation Dendritic Cell Comprising Ginsenoside Rg3 and Method for Producing Next-Generation Dendritic Cell Using the Same

  • 2018

    - Completed construction of a new plant in Ulsan for Biochemical Division

    - Launched a new cosmetics line 'Cellgram-S'

  • 2017

    - 1st Clinical trial for alcoholic cirrhosis treatment using stem cells (Cellgram-Liver), approved in US FDA

    - Applied for the approval of the domestic conditional permit for alcoholic cirrhosis treatment using stem cells (Cellgram-Liver)

    - Launched a new cosmetics line ‘Celbyten (Cx10)’

    - Awarded ‘2017 Health and Medical Technology Contributor' from the Minister of Health and Welfare

  • 2016

    - Selected as 'Innovative Pharmaceutical Company' by the Ministry of Health and Welfare

    - Selected as 'Global Leading Company' by Korea Industrial Complex Corporation

    - Awarded ‘the 2016 Venture Activation Award’, by the Minister of Trade, Industry and Energy Award

    - Hyun-soo Kim, CEO established a stem cell medical institution 'Kim Hyun-soo Clinic'

  • 2015

    - Launching the new Stem cell media cosmetic line ‘Stem-C’

  • 2014

    - Changed representative system (Kim Seong Rae selected as an representative)

    - Selected as ‘A Promising Export SME' (Small and Medium Business Administration)

    - Clinical study for commercialization of critical lower limb ischemia using stem cell(Cellgram-CLI) (IND-I phase) approved – MFDS(KFDA)

    - Clinical study for commercialization of impotence drug(Cellgram-ED) (IND-I phase) approved – MFDS(KFDA)

    - Organic phosphorus flame retardant and manufacturing method thereof

  • 2013

    - Small scale merger of IDB- Chem Co., Ltd.

    - Obtained SFDA hygien certificate of China

    - Commenced OEM business of cosmetics containing stem cell culture media

  • 2012

    - Acquisition of IDB- Chem Co., Ltd. (forerunner of Biochemical Business Division)

    - Clinical study for commercialization of alcoholic cirrhosis drug using stem cell(Cellgram-Liver) (IND-III phase) approved – KFDA

  • 2011

    - Changed its name to ‘Pharmicell Co., Ltd.'

    - The world first stem cell drug, ‘Hearticellgram-AMI’ approved - KFDA

    - Won grand prize at Public Health Industry Technology Award in the area of industrial development (Ministry of Health and Welfare)

  • 2010

    - Completed Seongnam GMP factory

  • 2009

    - Commenced stem cell culture media cosmetic products

  • 2008

    - Registered patent : USA patent with dendritic cell production technology for anticancer immune treatment (No.7390658)

  • 2007

    - Selected as ‘The World Best Next Generation Product Corporation' (Ministry of Knowledge and Economy)

    - Clinical study for commercialization of spinal cord injury drug using stem cell (IND-II/III phase) approved - KFDA

    - Registered patent: nerve cell production technology, USA (No. 7229827), Japan(No. 3976190), Australia(No. 2003273118)

  • 2006

    - Clinical study for commercialization of acute myocardial infarction drug, ‘Hearticellgram-AMI’, using stem cell(IND-II/III phase), approved – KFDA

  • 2005

    - Won the grand prize at Public Health Industry Technology Award in the area of research(Ministry of Health and Welfare)

    - Clinical study for commercialization of acute cerebral infarction drug using stem cell (IND-III phase) approved - KFDA

  • 2004

    - Commenced adult stem cell banking business

    - Registered patent: high-functional dendritic cell production technology for anticancer immune treatment using stem cell (No. 0429140)

    - Registered patent: nerve cell production technology for treatment of brain/nervous system disease using stem cell (No. 0449141)

  • 2003

    - Opened cell treatment center in Wonju Severance Christian Hospital

  • 2002

    - Established the company